Literature DB >> 19908318

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.

Dan Jones1, Hui Yao, Angela Romans, Caroline Dando, Sherry Pierce, Gautam Borthakur, Amy Hamilton, Carlos Bueso-Ramos, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian.   

Abstract

In cancer genomes, changes observed during tumor progression can be difficult to separate from nonspecific accumulation of cytogenetic changes due to cancer-associated genetic instability. We studied genetic changes occurring over time in cancers presenting with a relatively simple karyotype, namely two related core-binding factor (CBF) acute myeloid leukemias (AMLs), to assess how specific chromosomal changes are selected based on tumor subtype and acquired somatic mutations. Expression profiles for DNA replication/repair genes and the mutation status of KRAS, NRAS, FLT3, and KIT were compared with the karyotypic changes at diagnosis and relapse(s) in 94 cases of inv(16)(p13.1q22)-AML and 82 cases of t(8;21)(q22;q22)-AML. The majority of both AML types demonstrated a simple aneuploid pattern of cytogenetic progression, with highly distinctive patterns of chromosome copy number changes, such as +22 and +13 exclusively in inv(16)-AML and -Y and -X in t(8;21)-AML. Selection of certain cytogenetic changes correlated with particular somatic mutations, such as +8 with RAS mutation, and absence of kinase pathway mutations in t(8;21)-AML with localized deletions at chromosome band 9q22. Alterations in transcript levels of mitotic spindle kinases such as CHEK1, AURKA, and AURKB were associated with the aneuploid progression pattern, particularly in t(8;21) cases. Despite the similarity in the initiating genetics of the two CBF AML types, highly tumor-specific patterns of limited aneuploidy are noted that persist and continue to accumulate at relapse. Thus, activation of genetic instability, possibly through mitotic spindle dysregulation, leads rapidly to the selection of advantageous single chromosome aneuploidy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19908318      PMCID: PMC4161977          DOI: 10.1002/gcc.20732

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  36 in total

1.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature.

Authors:  Li Huang; Lynne V Abruzzo; Jose R Valbuena; L Jeffrey Medeiros; Pei Lin
Journal:  Am J Clin Pathol       Date:  2006-02       Impact factor: 2.493

3.  Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22).

Authors:  Jose R Valbuena; L Jeffrey Medeiros; George Z Rassidakis; Suyang Hao; C Daniel Wu; Lei Chen; Pei Lin
Journal:  Am J Clin Pathol       Date:  2006-08       Impact factor: 2.493

4.  KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.

Authors:  Susanne Schnittger; Tobias M Kohl; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Karsten Spiekermann; Claudia Schoch
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

5.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.

Authors:  B F Goemans; C M Zwaan; M Miller; M Zimmermann; A Harlow; S Meshinchi; A H Loonen; K Hählen; D Reinhardt; U Creutzig; G J L Kaspers; M C Heinrich
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

6.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

Authors:  Yue-Ying Wang; Guang-Biao Zhou; Tong Yin; Bing Chen; Jing-Yi Shi; Wen-Xue Liang; Xiao-Long Jin; Jian-Hua You; Guang Yang; Zhi-Xiang Shen; Jue Chen; Shu-Min Xiong; Guo-Qiang Chen; Feng Xu; Yi-Wei Liu; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-13       Impact factor: 11.205

7.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Authors:  Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

8.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

Authors:  N Boissel; H Leroy; B Brethon; N Philippe; S de Botton; A Auvrignon; E Raffoux; T Leblanc; X Thomas; O Hermine; B Quesnel; A Baruchel; G Leverger; H Dombret; C Preudhomme
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

9.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Authors:  Roberto Cairoli; Alessandro Beghini; Giovanni Grillo; Gianpaolo Nadali; Francesca Elice; Carla Barbara Ripamonti; Patrizia Colapietro; Michele Nichelatti; Laura Pezzetti; Monia Lunghi; Antonio Cuneo; Assunta Viola; Felicetto Ferrara; Mario Lazzarino; Francesco Rodeghiero; Giovanni Pizzolo; Lidia Larizza; Enrica Morra
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

10.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Authors:  R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

View more
  9 in total

Review 1.  Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

Authors:  Xi Quan; Jianchuan Deng
Journal:  Mol Clin Oncol       Date:  2020-05-25

2.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 3.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Authors:  Susumu Goyama; James C Mulloy
Journal:  Int J Hematol       Date:  2011-05-03       Impact factor: 2.490

4.  Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

Authors:  Naval Daver; Theresa Liu Dumlao; Farhad Ravandi; Sherry Pierce; Gautam Borthakur; Naveen Pemmaraju; Aziz Nazha; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Jorges Cortes; Hagop Kantarjian; Alfonso Quintás-Cardama
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-10

5.  Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.

Authors:  Yuichi Ishikawa; Naomi Kawashima; Yoshiko Atsuta; Isamu Sugiura; Masashi Sawa; Nobuaki Dobashi; Hisayuki Yokoyama; Noriko Doki; Akihiro Tomita; Toru Kiguchi; Shiro Koh; Heiwa Kanamori; Noriyoshi Iriyama; Akio Kohno; Yukiyoshi Moriuchi; Noboru Asada; Daiki Hirano; Kazuto Togitani; Toru Sakura; Maki Hagihara; Tatsuki Tomikawa; Yasuhisa Yokoyama; Norio Asou; Shigeki Ohtake; Itaru Matsumura; Yasushi Miyazaki; Tomoki Naoe; Hitoshi Kiyoi
Journal:  Blood Adv       Date:  2020-01-14

Review 6.  Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

Authors:  Habsah Aziz; Chow Y Ping; Hamidah Alias; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-12-07       Impact factor: 5.810

Review 7.  Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.

Authors:  Hubert Hackl; Ksenia Astanina; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2017-02-20       Impact factor: 17.388

Review 8.  Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Wenlan Chen; Hui Xie; Hongxiang Wang; Li Chen; Yi Sun; Zhichao Chen; Qiubai Li
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

9.  Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Authors:  Sabine Kayser; Michael Kramer; David Martínez-Cuadrón; Justin Grenet; Klaus H Metzeler; Zuzana Sustkova; Marlise R Luskin; Andrew M Brunner; Michelle A Elliott; Cristina Gil; Sandra Casal Marini; Zdeněk Ráčil; Petr Cetkovsky; Jan Novak; Alexander E Perl; Uwe Platzbecker; Friedrich Stölzel; Anthony D Ho; Christian Thiede; Richard M Stone; Christoph Röllig; Pau Montesinos; Richard F Schlenk; Mark J Levis
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.